Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laborat…
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
Yesterday | ||
 BDX Completes PREVENT Trial Enrollment for Phasix Mesh Study BD concludes PREVENT trial enrollment, advancing Phasix Mesh toward a potential FDA submission for incisional hernia prevention. | ||
 Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery? Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside. | ||
This week | ||
 Are Wall Street Analysts Predicting Becton, Dickinson and Company Stock Will Climb or Sink? Becton, Dickinson and Company has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects. | ||
Older | ||
 WST Stock Surges 38.1% Since March-End: What's Fueling the Rally? West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally. | ||
 How Much More Can Boston Scientific Stock Move After Losing Half Its Value? Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes. | ||
 Buy, Sell, or Hold These 4 Dividend Kings After Earnings: BDX, ED, EMR, PH Four Dividend Kings - Becton, Dickinson and Company (BDX), Consolidated Edison (ED), Emerson Electric (EMR), and Parker-Hannifin (PH) - reported earnings last week. | ||
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains. | ||
 Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins. | ||
 Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales. | ||
 Jim Cramer Sees Cheap Valuation in Becton, Dickinson (BDX) After Q3 Beat and Raised Guidance On August 6, Jim Cramer highlighted Becton, Dickinson and Company (NYSE:BDX) on CNBC’s Mad Money following its third-quarter fiscal 2026 financial report and said: This morning, we got a very strong quarter from BD. That’s the big medical technology and supply play… That was formerly known as Becton, Dickson. This was the first full quarter […] | IInsider Monkey | |
 We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks. Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend coverage story is quietly getting stronger. | ||
 Becton Dickinson (BDX) Stock Sees Modest Fair Value Lift After Mixed Analyst Views Becton Dickinson has seen its analyst fair value estimate move from US$181.23 to US$189.58, signaling a refreshed price target framework that investors are watching closely. This shift reflects how recent research is weighing the solid fiscal Q3 beat, product updates, and mixed views on 2027 utilization and margin risk. As you read on, you will see how these moving pieces shape the evolving narrative around Becton Dickinson and what that could mean for your own assessment of the stock. Stay... | ||